Curcumin Added to Standard Chemo Tested in Metastatic Colorectal Cancer Trial
A Phase 2 trial explores whether oral curcumin can enhance Avastin/FOLFIRI chemotherapy outcomes in patients with unresectable colorectal metastases.
Summary
This completed Phase 2 clinical trial, sponsored by Gachon University Gil Medical Center in South Korea, investigated whether adding an oral curcumin supplement to standard Avastin/FOLFIRI chemotherapy could improve outcomes for colorectal cancer patients with unresectable metastases. Curcumin, the active compound in turmeric, has demonstrated anti-inflammatory and anti-tumor properties in laboratory settings, making it a plausible candidate to enhance conventional cancer treatment. The trial enrolled patients beginning Avastin/FOLFIRI and administered curcumin for the duration of chemotherapy. While the abstract does not disclose efficacy or safety results, the completion of this study represents meaningful progress in evaluating natural compounds as adjuncts to oncology regimens. Full published results are needed to assess whether curcumin offers a clinically meaningful benefit.
Detailed Summary
Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and patients with unresectable metastatic disease face limited treatment options beyond systemic chemotherapy. The standard Avastin/FOLFIRI regimen — combining the anti-angiogenic antibody bevacizumab with a fluorouracil-based chemotherapy backbone — offers meaningful but often temporary disease control. Researchers have long sought adjuncts that could improve response rates, reduce toxicity, or extend progression-free survival.
Curcumin, the principal bioactive polyphenol derived from turmeric, has attracted scientific attention for its multi-pathway anti-tumor activity. Preclinical data suggest curcumin can inhibit NF-κB signaling, suppress angiogenesis, induce cancer cell apoptosis, and modulate inflammatory pathways that tumors exploit for survival and spread. These mechanisms overlap with and potentially complement those of bevacizumab and fluorouracil, providing a scientific rationale for combination testing.
This Phase 2 trial, registered as NCT02439385 and sponsored by Gachon University Gil Medical Center, enrolled colorectal cancer patients with unresectable metastases who were initiating Avastin/FOLFIRI. Participants received an oral curcumin-containing supplement for the full duration of their chemotherapy course, or until withdrawal. The trial has been marked as completed, suggesting recruitment and follow-up concluded as planned.
Unfortunately, the publicly available abstract does not report efficacy endpoints, response rates, survival data, or adverse event profiles. These critical outcomes remain inaccessible without the full published manuscript, limiting meaningful clinical interpretation at this stage.
If curcumin proves to enhance chemotherapy response or reduce side effects in the published results, it could represent a low-cost, widely available adjunct for oncologists treating metastatic colorectal cancer. However, curcumin's notoriously poor bioavailability remains an important caveat. The choice of formulation used in this trial — and whether enhanced-absorption curcumin was employed — will be crucial to interpreting any findings and their real-world applicability.
Key Findings
- Phase 2 trial completed testing oral curcumin as an adjunct to Avastin/FOLFIRI in metastatic colorectal cancer.
- Curcumin's anti-inflammatory and anti-angiogenic mechanisms may complement bevacizumab-based chemotherapy.
- Full efficacy and safety results are not yet publicly available from the abstract alone.
- Trial completion suggests feasibility of combining curcumin supplementation with active chemotherapy regimens.
- Curcumin bioavailability and specific formulation used remain key variables for interpreting outcomes.
Methodology
This is a Phase 2 single-arm or comparative trial enrolling colorectal cancer patients with unresectable metastases starting Avastin/FOLFIRI chemotherapy. Oral curcumin supplement was administered concurrently for the duration of chemotherapy. Specific details on dosing, formulation, sample size, and control arm design are not disclosed in the available abstract.
Study Limitations
This summary is based on the abstract only; full efficacy, safety, and methodology data are not publicly available. Curcumin's poor oral bioavailability is a well-documented challenge that may significantly affect outcomes depending on the formulation used. No results, sample size, or control arm details are disclosed, making clinical conclusions premature.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.